OssDsign (OSSD) ABGSC Investor Days summary

Financial performance and growth

• Achieved 65% sales growth year-over-year in Q1, with 60% in constant currency and gross margin rising to 96.4%.

• Last 12 months' sales reached $151 million, up 83% from the previous year, marking the best-ever operating result with adjusted EBIT at minus $5.6 million.

• Surpassed the milestone of 10,000 U.S. patients treated with OssDsign Catalyst, a twentyfold increase in two years.

• U.S. spinal orthobiologics market is valued at $1.8 billion, with 70% of the global market and strong underlying growth.

• Access to nearly 10% of the U.S. market achieved, with significant runway remaining for expansion.

Clinical evidence and product innovation

• Multiple studies and publications released, including preclinical, clinical, and real-world data, confirming high and rapid fusion rates.

• OssDsign Catalyst demonstrated dual bone growth pathways, outperforming comparable synthetics in challenging avascular environments.

• Ongoing Propel registry has enrolled over 300 patients, with upcoming publication of the first 100-patient cohort.

• Recent ovine model study showed OssDsign Catalyst generated functional bone faster than competitors in bloodless environments.

• Ten new publications since a strategic shift last year, building a robust clinical repository.

Market trends and strategic priorities

• Aging population and shift from autograft/allograft to synthetics are driving market growth.

• Surgeons increasingly prefer new-generation synthetics due to improved efficacy.

• Main growth currently comes from surgeons already using synthetics, with younger surgeons more open to adopting new technologies.

• OssDsign is developing two new products, including solutions for minimally invasive surgery and larger spinal constructs.

• Strategic focus remains on expanding U.S. market access, leveraging clinical evidence, and broadening the product portfolio.